Related Experiment Video
Updated: Jul 24, 2026
11:10
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1
R P Moseley1, J C Benjamin, R D Ashpole
1Frenchay Hospital, Bristol, UK.
Journal of Neurology, Neurosurgery, and Psychiatry
|March 1, 1991
Summary
Intrathecal I-131 labelled monoclonal antibody HMFG1 showed clinical responses in two of seven carcinomatous meningitis patients. While some patients experienced toxicity, one long-term survivor highlights potential benefits of this targeted therapy.
Area of Science:
- Oncology
- Immunotherapy
- Radiopharmaceuticals
Background:
- Carcinomatous meningitis presents a significant challenge in advanced cancer care.
- Intrathecal therapy offers a direct route for drug delivery to the central nervous system.
- Monoclonal antibodies provide targeted delivery mechanisms for cancer treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of intrathecal I-131 labelled monoclonal antibody HMFG1 in patients with carcinomatous meningitis.
- To assess clinical responses and identify potential toxicities associated with this treatment modality.
Main Methods:
- Seven patients with carcinomatous meningitis received intrathecal administration of I-131 labelled HMFG1.
- Clinical responses, including survival, and adverse events were closely monitored.
- Radiological assessment for subarachnoid space changes was performed.
Main Results:
- Two out of seven patients demonstrated clinical responses to the treatment.
- One patient achieved long-term survival of 32 months.
- Adverse events included aseptic meningitis (4/7), seizures (2/7), and myelosuppression (3/7).
- Partial obliteration of the subarachnoid space was noted in advanced disease.
Conclusions:
- Intrathecal I-131 labelled HMFG1 demonstrated potential therapeutic activity in carcinomatous meningitis.
- The treatment was associated with significant toxicities, including neurological and hematological adverse events.
- Advanced disease characteristics, such as subarachnoid space obliteration, may impact treatment delivery and outcomes.
